8-K: Paysign Reports Strong Q1 2026 Results with 51% Revenue Growth

Paysign, Inc. announced first quarter 2026 financial results, showcasing a 50.8% year-over-year revenue increase to $28.04 million, driven by significant growth in its patient affordability and plasma revenue segments, alongside substantial margin expansion.

Summary

• Paysign, Inc. reported first quarter 2025 revenues of $28.04 million, a 50.8% increase from $18.6 million in the prior year's first quarter.
• Pharma industry revenue surged by 81.9% to $15.68 million, adding 45 net patient affordability programs in the last twelve months, reaching 135 active programs.
• Plasma revenue grew by 24.9% to $11.75 million, with a net increase of 89 plasma centers over the past year, totaling 573 centers.
• Operating margin expanded significantly to 23.8% from 13.4% in the first quarter of 2025.
• Net income rose to $5.44 million ($0.09 per diluted share) from $2.59 million ($0.05 per diluted share) in Q1 2025.
• Adjusted EBITDA increased by 113.4% to $10.59 million ($0.17 per diluted share) from $4.96 million ($0.09 per diluted share) in Q1 2025.
• The company ended the quarter with $20.55 million in unrestricted cash and no bank debt.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a very positive filing, with exceptional financial performance, strong growth across key segments, significant margin expansion, and a reiteration of confident future outlook.

Positives

• Exceptional top- and bottom-line results for Q1 2026, exceeding guidance across all income statement lines.
• Revenue growth of 50.8% year-over-year, reaching $28.04 million.
• Significant increase in pharma revenue (81.9%) driven by new patient affordability programs.
• Strong growth in plasma revenue (24.9%) and an increase in plasma centers.
• Operating margin expansion to 23.8% from 13.4% year-over-year.
• Net income more than doubled to $5.44 million ($0.09 EPS) from $2.59 million ($0.05 EPS).
• Adjusted EBITDA more than doubled to $10.59 million ($0.17 Adj. EPS) from $4.96 million ($0.09 Adj. EPS).
• Maintained a strong balance sheet with $20.55 million in unrestricted cash and zero bank debt.

Negatives

• Cost of revenues increased by 42.2% due to higher call center support, new customer service center, and employee costs.
• Stock compensation expense increased by 91.0% to $1.28 million.
• Depreciation and amortization increased by 46.4% due to amortization of intangible assets and software development costs.
• The effective tax rate increased to 27.2% from 20.5% in the prior year's quarter.
• Restricted cash increased by 10.4% to $158.95 million, primarily due to customer program deposits and funds on card.
• The company exited the quarter with fewer plasma centers (573) than at the end of 2025 (595), due to sales to competitors and closure of underperforming centers.

Risks

• Inability to continue current growth rates in future periods.
• Risk of not adding new patient affordability programs or retaining existing ones at anticipated rates.
• Plasma center customers may switch to competing providers or close centers, reducing revenue.
• The company's outlook and guidance may not be achieved due to factors within or outside its control.
• Economic downturn could reduce customer base and demand for products and services.
• Operating in a highly regulated environment and potential non-compliance with laws and regulations.
• Changes in laws, regulations, credit card association rules, or industry standards affecting the business.
• Potential restrictions on pharmaceutical patient affordability or copay assistance programs.

Future Outlook

Paysign reiterates its full-year 2026 guidance, expecting revenue growth between 30% and 35%, with plasma and pharma contributing roughly equally. The company anticipates margins expanding across the income statement and net income nearly doubling over 2025. For the second quarter of 2026, revenue is projected between $26.2 million and $26.7 million, with net income between $3.5 million and $4.0 million.

Management Comments

• "Paysign delivered a strong start to 2026, with exceptional top- and bottom-line results that are consistent with our strategic direction and the scalability of the platform we've built."
• "Our plasma donor compensation business continues to perform exceptionally well, and the reception to our SaaS solutions from collectors and plasmapheresis manufacturers across the U.S., Europe and Asia reinforces our conviction that purpose-built technology, backed by deep industry expertise, creates a competitive advantage."
• "Patient affordability emerged as our largest revenue contributor in the quarter, with 135 active programs and a strong pipeline that reflects the trust pharmaceutical manufacturers place in Paysign to help patients access and afford the therapies they need."
• "As this business grows, we are positioned to deliver long-term value for our shareholders, our customers and the patients we serve."
• "Our first quarter results exceeded guidance across every line of the income statement, with revenue, operating margin and net income all finishing above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift toward patient affordability."
• "The momentum from the first quarter supports our confidence in achieving the upper half of our guidance ranges."

Industry Context

StockSavvy.ai notes that Paysign's strong Q1 2026 performance, particularly the 51% revenue growth driven by patient affordability and plasma solutions, aligns with broader trends in healthcare fintech. The increasing demand for patient access to therapies and efficient payment processing in the life sciences sector are key drivers for companies like Paysign. The company's focus on SaaS solutions and deep industry expertise appears to be a successful strategy in a competitive landscape.

Comparison to Industry Standards

• Paysign's revenue growth of 50.8% in Q1 2026 significantly outpaces the typical growth rates seen in the broader fintech and healthcare IT sectors, which often range from 10-25% annually.
• The expansion of operating margin to 23.8% is robust, especially for a company in a growth phase, indicating strong operational leverage. Many SaaS companies in the healthcare space aim for operating margins in the mid-to-high teens.
• The company's Adjusted EBITDA margin of 37.8% demonstrates strong profitability relative to revenue, suggesting efficient cost management and a scalable business model, which is a benchmark for high-performing companies in the payment processing and healthcare technology industries.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased net income, EPS, and EBITDA, and reiterated positive outlook.
• Customers (Pharma & Plasma): Continued provision of essential patient affordability and donor compensation solutions, with expanded program offerings.
• Patients: Improved access to therapies through enhanced patient affordability programs.
• Employees: Potential for continued investment in growth and operations, though increased stock compensation expense is noted.

Next Steps

• Continue to invest for profitable growth.
• Execute against the financial framework communicated.
• Exit Q2 2026 with 147-150 active patient affordability programs.
• Exit Q2 2026 with 555-560 plasma centers.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with significant year-over-year growth in revenue, net income, and EBITDA, coupled with strong margin expansion. The company exceeded its own guidance, has a robust balance sheet with no debt, and reiterates a confident outlook for the full year. This combination of strong execution and positive future prospects strongly suggests a 'strong buy' recommendation for investors.

Keywords

Paysign, Patient Affordability, Pharma Revenue, Plasma Revenue, EBITDA, Revenue Growth, Financial Results, 8-K Filing